📄 Showing the "Simple" version — "Popular" is not ready yet. Add it to favorites to help prioritize it. Ask for the full read

The light bulb turns on only in the room where you need it. That's roughly how photoactivatable drugs work: they 'switch on' only where light is directed, leaving the rest of the body untouched. This is especially important in cancer treatment: conventional chemotherapy hits all dividing cells indiscriminately, causing severe side effects. But here, you can illuminate just the tumor, and the drug goes to work.

Creating such a drug is no easy feat. The molecule must be stable in the dark, activate quickly in light, and bind tightly to its target protein — in this case, PARP1, which helps cancer cells repair their DNA. To avoid manually screening millions of options, the scientists built a computational pipeline. First, they virtually 'docked' 5 million molecules to the protein and selected those that bind differently in the dark versus light. Then, using machine learning, they predicted their color, stability, and efficacy. In the end, they synthesized 10 of the most promising candidates and tested them in the lab.

The best molecule showed a 15-fold increase in PARP1 inhibition when exposed to green light (519 nm). It's like a switch that only turns under light: in the dark, the drug barely works, but when illuminated, it actively suppresses the protein. There is a catch, though: in an aqueous environment, like inside a cell, the molecule quickly loses its active form. But the approach itself (combining computational screening, quantum chemistry, and machine learning) paves the way for more precise and safer drugs of the future. And then the light bulb will turn on exactly where it's needed, without any extra light.